Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12083268-B2
Publication Date
2024-09-10
Expiration Date
Abstract
The present invention relates to a handheld vibrating mesh nebuliser for delivery of a medicament to the respiratory system in therapy. The present invention also relates to a supply container for loading the nebuliser with liquid medicament. The present invention also relates to a kit for delivery of a medicament to a respiratory system and a method of loading a vibrating mesh nebuliser with liquid medicament from a supply container. The present invention also relates to compositions for use in a method of treatment of a respiratory disease in a patient by therapy.
Core Innovation
The invention relates to a method of treating a respiratory disease in a patient by administering a liquid medicament to the respiratory system using a vibrating mesh nebuliser. The vibrating mesh nebuliser comprises a housing having a reservoir for the liquid medicament, and the liquid medicament includes an unfractionated heparin or a physiologically acceptable salt thereof or a derivative thereof having an average molecular weight of from >8 to 40 kDa, together with an inorganic salt selected from specified inorganic salts of lithium, sodium, potassium, magnesium, calcium, aluminium, zinc and ammonium.
The liquid medicament is constrained by the concentration of the unfractionated heparin, or physiologically acceptable salt or derivative, being from 15 to 40 mg/mL, and the total concentration of the inorganic salt being from 10 to 300 mM. The method is directed to respiratory diseases characterised by mucous hyper secretion or elevated mucous viscosity, or selected from chronic obstructive pulmonary disease, emphysema, cystic fibrosis, bronchitis, asthma, bronchiectasis, primary ciliary dyskinesia, pneumonia, sinusitis, sinus congestion, influenza, a cold, a viral infection, a bacterial infection, and a fungal infection.
In one embodiment, the liquid medicament further comprises a second therapeutic agent and/or DNase in addition to the unfractionated heparin, or physiologically acceptable salt or derivative, and the specified inorganic salt. Where a second therapeutic agent is present, both the second therapeutic agent and the unfractionated heparin, or only the second therapeutic agent, are intended to have a therapeutic effect, while the heparin is intended to facilitate delivery of the second therapeutic agent to its target site in the body.
Claims Coverage
The partial content provides two independent claims. The inventive features center on vibrating mesh nebuliser administration of a heparin-containing liquid medicament with specified inorganic salt and quantitative concentration limits, applied to defined respiratory diseases; one claim also includes a second therapeutic agent and/or DNase.
Vibrating mesh nebuliser administration with heparin inorganic-salt medicament for respiratory disease treatment
A method of treating a respiratory disease in a patient by administering a liquid medicament to the respiratory system by a vibrating mesh nebuliser, where the vibrating mesh nebuliser comprises a housing having a reservoir for the liquid medicament; the liquid medicament comprises an unfractionated heparin or a physiologically acceptable salt thereof or a derivative thereof having an average molecular weight of from >8 to 40 kDa and an inorganic salt selected from specified salts of lithium, sodium, potassium, magnesium, calcium, aluminium, zinc and ammonium; the concentration of the unfractionated heparin, or salt or derivative, is from 15 to 40 mg/mL; and the total concentration of the inorganic salt is from 10 to 300 mM.
Vibrating mesh nebuliser heparin inorganic-salt medicament with second therapeutic agent and/or DNase
A method of treating a respiratory disease in a patient by administering a liquid medicament to the respiratory system by a vibrating mesh nebuliser, where the liquid medicament comprises an unfractionated heparin, or physiologically acceptable salt or derivative, having an average molecular weight of from >8 to 40 kDa, an inorganic salt selected from specified salts of lithium, sodium, potassium, magnesium, calcium, aluminium, zinc and ammonium, and a second therapeutic agent and/or DNase; the heparin concentration is from 15 to 40 mg/mL and the total inorganic salt concentration is from 10 to 300 mM; and where a second therapeutic agent is present, both the second therapeutic agent and the heparin are intended to have a therapeutic effect, or only the second therapeutic agent is intended to have a therapeutic effect while the heparin is intended to facilitate delivery of the second therapeutic agent to its target site.
The claims are anchored on vibrating mesh nebuliser delivery of a liquid medicament containing unfractionated heparin, or a physiologically acceptable salt or derivative, with specified inorganic salt and concentration ranges, for respiratory diseases characterised by mucous hyper secretion or elevated mucous viscosity or selected from the listed diseases and infections. One independent claim further includes a second therapeutic agent and/or DNase and defines the intended therapeutic effect or delivery-facilitation role of the heparin.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?